GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Degree of Financial Leverage

Innoveren Scientific (Innoveren Scientific) Degree of Financial Leverage : 1.31 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Innoveren Scientific's Degree of Financial Leverage for the quarter that ended in Sep. 2023 was 1.31. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Innoveren Scientific's Degree of Financial Leverage or its related term are showing as below:

IVRN's Degree of Financial Leverage is ranked worse than
73.7% of 1498 companies
in the Biotechnology industry
Industry Median: 0.97 vs IVRN: 1.31

Innoveren Scientific Degree of Financial Leverage Historical Data

The historical data trend for Innoveren Scientific's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific Degree of Financial Leverage Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 0.19 0.89 8.66 0.33

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.33 -3.17 1.85 1.31

Competitive Comparison of Innoveren Scientific's Degree of Financial Leverage

For the Biotechnology subindustry, Innoveren Scientific's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoveren Scientific's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's Degree of Financial Leverage falls into.



Innoveren Scientific Degree of Financial Leverage Calculation

Innoveren Scientific's Degree of Financial Leverage for the quarter that ended in Sep. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -4.33 (Sep. 2023) / -45.95 (Sep. 2022) - 1 )/( -2.821 (Sep. 2023) / -9.212 (Sep. 2022) - 1 )
=-0.9058/-0.6938
=1.31***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Innoveren Scientific  (OTCPK:IVRN) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Innoveren Scientific Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoveren Scientific (Innoveren Scientific) Business Description

Traded in Other Exchanges
N/A
Address
2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Executives
Fwhc Holdings, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone director 201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel officer: Chief Financial Officer 201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif officer: President and C.E.O. 19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc 10 percent owner 2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch 10 percent owner C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc 10 percent owner 334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner 10 percent owner 3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky director 2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne director, officer: Chief Executive Officer 201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford director 714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615